Letrozole 25

ACTIVE HALF-LIFE 2-3 days
CLASSIFICATION Non-steroidal aromatase inhibitor
DOSAGE 0.5-1 mg over a period of 1 to 3 days
ACNE None
WATER RETENTION None
HBR None
HEPATOTOXICITY None
AROMATIZATION None
MANUFACTURER Hilma Biocare
LAB TEST Refer to Document
WAREHOUSE EU Warehouse 3
SUBSTANCE Letrozole

Letrozole is a powerful antitumor agent classified as a non-steroidal selective aromatase inhibitor. It is primarily used in breast cancer treatment and is a key component of post-menopausal therapy for women. Athletes have increasingly turned to Letrozole for its impressive anti-estrogenic properties and capability to enhance muscle definition. Remarkably, Letrozole is up to five times more effective than Anastrozole (Arimidex) at reducing the adverse effects linked with anabolic steroid use. By lowering estrogen levels in the body, it provides substantial protection against elevated estradiol.

Athletes incorporating Letrozole into their regimen can effectively diminish estrogen levels and prevent aromatization.

Some common side effects associated with Letrozole may include skin rashes, nausea, abdominal discomfort, fatigue, dizziness, headaches, elevated low-density cholesterol levels, and increases in liver enzymes.

Before beginning Letrozole, it is recommended to conduct preliminary blood tests. This can lead to a dramatic reduction in estradiol levels, enhancing the overall efficacy of your cycle. Letrozole serves as a potent anti-estrogenic agent and is frequently utilized during post-cycle therapy (PCT).

While Letrozole is exceptionally effective during PCT, it can also be synergistically combined with clomiphene or other steroids within a cycle.